Market Place
Sourcing Support
Enforcement Report - Week of October 18, 2023
18 Oct 2023 //
FDA
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME
27 Sep 2023 //
GLOBENEWSWIRE
SCYNEXIS and Hansoh Announce NMPA Acceptance of NDA for Ibrexafungerp
20 Jul 2023 //
GLOBENEWSWIRE
SCYNEXIS Achieves $25M GSK Development Milestone
21 Jun 2023 //
CONTRACTPHARMA
SCYNEXIS Reports Closing of Agreement with GSK for BREXAFEMME
12 May 2023 //
GLOBENEWSWIRE
Scynexis to Present Ibrexafungerp Data at the 33rd Annual ECCMID April 15-18
13 Apr 2023 //
GLOBENEWSWIRE
GSK and Scynexis announce an exclusive agreement to commercialise Brexafemme
31 Mar 2023 //
PRESS RELEASE
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME®
01 Dec 2022 //
GLOBENEWSWIRE
BARDA Invests in Development of Antifungal Treatments
18 Nov 2022 //
CONTRACTPHARMA
SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp
07 Nov 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Interim Data of Ibrexafungerp Ongoing Phase 3
08 Sep 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Data from PIII CANDLE Study of Oral Ibrexafungerp
04 Aug 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Positive Data from PIII CANDLE Nested Study of Ibrexafungerp
19 Jul 2022 //
GLOBENEWSWIRE
SCYNEXIS to Present Data from CANDLE Nested Sub-Study of Ibrexafungerp
14 Jul 2022 //
GLOBENEWSWIRE
SCYNEXIS Initiates New PIIIb Study (VANQUISH) for Oral Ibrexafungerp in WC
23 Jun 2022 //
GLOBENEWSWIRE
SCYNEXIS Submits sNDA of BREXAFEMME to FDA for Vaginal Yeast Infections
08 Jun 2022 //
GLOBENEWSWIRE
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp`s Potential
27 Apr 2022 //
GLOBENEWSWIRE
SCYNEXIS Secures Addn Commercial Insurance Formulary Coverage for BREXAFEMME
19 Apr 2022 //
GLOBENEWSWIRE
SCYNEXIS Announces Positive Results from Phase 3 CANDLE Study of Ibrexafungerp
10 Feb 2022 //
GLOBENEWSWIRE
BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary
20 Dec 2021 //
GLOBENEWSWIRE
SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL
29 Nov 2021 //
GLOBENEWSWIRE
SCYNEXIS Announces Successful Completion of Phase 1 Trial (IV) Ibrexafungerp
09 Nov 2021 //
GLOBENEWSWIRE
SCYNEXIS Announces Preclinical Data at the 10th Trends Medical Mycology Meeting
11 Oct 2021 //
GLOBENEWSWIRE
SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing
29 Sep 2021 //
GLOBENEWSWIRE
SCYNEXIS Announces U.S. Availability of BREXAFEMME
22 Sep 2021 //
GLOBENEWSWIRE
SCYNEXIS Announces Hansoh`s Application to NMPA for Ph3 Trial of Ibrexafungerp
13 Sep 2021 //
GLOBENEWSWIRE
SCYNEXIS Reports Second Quarter 2021 Financial Results and Corporate Update
16 Aug 2021 //
GLOBENEWSWIRE
SCYNEXIS Confirms BREXAFEMME Qualifies for 10 Years of Regulatory Exclusivity
09 Jun 2021 //
GLOBENEWSWIRE
SCYNEXIS Announces FDA Approval of BREXAFEMME®
02 Jun 2021 //
PRESS RELEASE
SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation
10 Dec 2020 //
SCYNEXIS
SCYNEXIS Announces FDA Acceptance and Priority Review of NDA
07 Dec 2020 //
FIRSTWORLDPHARMA
SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp
21 Oct 2020 //
PRESS RELEASE
SCYNEXIS Reports Successful Completion Pre-NDA Meetings with FDA Ibrexafungerp
29 Jul 2020 //
GLOBENEWSWIRE
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Ibrexafungerp
22 Jul 2020 //
GLOBENEWSWIRE
SCYNEXIS Announces Six Abstracts Pub by 30th ECCMID Highlighting Ibrexafungerp
06 May 2020 //
SCYNEXIS
Scynexis` new antifungal delivers in yeast infection phase 3
21 Apr 2020 //
PRESS RELEASE
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles
05 Mar 2020 //
GLOBENEWSWIRE
Scynexis completes patient enrollment for women’s health phase 3 study
13 Feb 2020 //
PHARMIWEB
